2024
Smouldering‐Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions
Scalfari A, Traboulsee A, Oh J, Airas L, Bittner S, Calabrese M, Dominguez J, Granziera C, Greenberg B, Hellwig K, Illes Z, Lycke J, Popescu V, Bagnato F, Giovannoni G. Smouldering‐Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions. Annals Of Neurology 2024, 96: 826-845. PMID: 39051525, DOI: 10.1002/ana.27034.Peer-Reviewed Original ResearchMultiple sclerosisProgression independent of relapse activityCognitive symptomsIndependent of relapse activitySuppression of relapseInternational consensus statementClinical implicationsRelapse activityTherapeutic suppressionClinical trialsConsensus statementFuture directionsTherapeutic targetRoutine practicePathological substrateProgressive independencePathological processes
2023
Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation
Oh J, Airas L, Harrison D, Järvinen E, Livingston T, Lanker S, Malik R, Okuda D, Villoslada P, de Vries H. Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation. Frontiers In Neurology 2023, 14: 1319869. PMID: 38107636, PMCID: PMC10722910, DOI: 10.3389/fneur.2023.1319869.Peer-Reviewed Original ResearchMultiple sclerosisClinical trialsMonitoring of MSMagnetic resonance imagingPositron emission tomographyDisability worseningKey unmetCentral pathologyEarly pathologyTreatment responseNew therapiesOcular imagingUnmet needResonance imagingEmission tomographyDisease pathologyNew therapeuticsPathologyNeuroimaging measuresTrialsLongitudinal studySclerosisClinicWorseningBiomarkers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply